Table 3.
Markers of kidney function in all groups of rats.
| Control | Eriodictyol | STZ | STZ + Eriodictyol | STZ + Eriodictyol + ML385 | ||
|---|---|---|---|---|---|---|
| Serum | Urea (mg/dL) | 5.2 ± 0.57 | 5.8 ± 0.72 | 33.5 ± 4.1 ab | 6.3 ± 0.74c | 30.2 ± 3.6 abd |
| Creatinine (mg/dL) | 0.63 ± 0.05 | 0.61 ± 0.04 | 1.8 ± 0.0.23 ab | 0.71 ± 0.12c | 2.9 ± 0.41 abd | |
| Urine | Volume (ml) | 11.4 ± 2.4 | 10.9 ± 1.7 | 17.5 ± 2.1 ab | 10.4 ± 2.9c | 18.5 ± 2.4 abd |
| Albumin (µg/dL) | 22.5 ± 1.7 | 25.4 ± 3.8 | 62.3 ± 5.7 ab | 31.3 ± 3.5 abc | 68.4 ± 6.3 abd | |
| Creatinine (µg/dL) | 65.7 ± 5.6 | 62.3 ± 6.3 | 22.8 ± 1.9 ab | 51.3 ± 3.9 abc | 25.1 ± 2.4 abd | |
| MCP-1 (pg/mL) | 178.3 ± 12.8 | 165.3 ± 15.7 | 438.2 ± 37.5 ab | 235.1 ± 19.2 abc | 458.1 ± 43.2 abd | |
| KIM-1 (ng/mL) | 1.56 ± 0.2 | 1.68 ± 0.2 | 4.65 ± 0.5 ab | 2.1 ± 0.4 abc | 4.30 ± 0.6 bd | |
| Nephrine (ng/mL) | 5.23 ± 0.4 | 4.88 ± 0.6 | 14.3 ± 1.8 ab | 6.7 ± 0.8 abc | 15.3 ± 1.8 bd |
Data are presented as means ± SD for n = 8 rats/group. Significance difference was considered if p < 0.05. (a): significantly differed with the control non-diabetic group; (b): significantly differed with the Eriodictyol-treated group; (c): significantly differed with STZ-treated diabetic rats; (d): significantly differed with STZ + Eriodictyol-treated group. ML385: a selective Nrf2 inhibitor.